Clinical data disclosed in November 2025 to be presented at medical meeting with new supportive translational data for both programsVispa-cel ...
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market ...
OXB and Bristol Myers Squibb (BMS) are expanding a partnership regarding manufacture and supply of lentiviral vectors for BMS’ CAR-T programs.
WuXi Biologics (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has signed a license and research service agreement with ...
Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief ...
Cellares has joined forces with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative ...
TECregen Appoints Drug Development Veteran Dr. Klaas P. Zuideveld as Chief Executive Officer to Lead Thymus Regeneration Platform into Clinical Development ...
The Chosun Ilbo on MSN
AlphaGenome decodes 98% genome for disease insights
Google DeepMind’s research team recently disclosed in the international academic journal *Nature* the development process of ...
US FDA grants orphan drug designation to Imviva Biotech’s CTD402 for the treatment of T-cell leukaemia and lymphoma: Boston Friday, January 30, 2026, 17:00 Hrs [IST] Imviva Biot ...
Study suggests that persistently activated ATF6α is a tumor driver, a potential stratification marker for immunotherapy response, and a therapeutic target for HCC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results